참고문헌
- D.B. Longley, D.P. Harkin and P.G. Johnston, 5-fluorouracil: mechanisms of action and clinical strategies, Nat. Rev. Cancer, 3, 330-338 (2003) https://doi.org/10.1038/nrc1074
- R.B. Diasio and B.E. Harris, Clinical pharmacology of 5-fluorouracil, Clin Pharmacokinet, 16, 215-237 (1989) https://doi.org/10.2165/00003088-198916040-00002
- R.B. Diasio, Oral DPD-inhibitory fluoropyrimdine drugs, Oncolosy (Huntingt), 14, 19-23 (2000)
- S. Cao, C. Frank, T. Shirasaka and Y.M. Rustum, 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer, CIin Cancer Res., 1, 839-845 (1995)
- M. Valdivieso, G.P. Bodey, J.A. Gottlieb and E.J. Freireich, Clinical Evaluation of ftorafur (Pyrimidine-deoxyribose N1-2'-furanidyl-5-Guorouracil), Cancer Res., 36, 1821-1824 (1976)
- M.I. Anttila, E.A. Sotaniemi, M.I. Kairaluoma, R.E. Mokka and H.T. Sundquist, Pharmacokinetics of ftorafur after intravenous and oral administration, Cancer Chemother Pharmacol, 10, 150-153 (1983)
- J.A. Benvenuto, J.G. Liehr, T. Winkler, D. Farquhar, R.M. Capiioli and T.L. Loo, Human urinary metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur), Cancer Res., 39, 3199-3201 (1979)
- D.H. Ho, W.P. Covington, R. Pazdur, N.S. Brown, J. Kuritani, R.A. Newman, M.N. Raber and I.H. Krakoff, Clinical pharmacology of combined oral uracil and ftorafur, Drug Metab. Dispos., 20, 936-940 (1992)
- H. Yuasa, J. Gu, Y. Hayashi and J. Watanabe, First-pass metabolism of 5-fluorouracil in rats, J. Pharm. Pharmacol, 50, 1019-1025 (1998)
- A.T. Wu, H.J. Schwandt, C. Finn and W. Sadee, Determination of ftorafur and 5-fluorouracil levels in plasma and urine, Res. Commun. Chem. Pathol. Pharmacol, 14, 89-102 (1976)
- W.R. Wrightson, S.R. Myers and S. Galandiuk, HPLC analysis of 5-FU and FdUMP in tissue and serum, Biochem Biophys Res. Commun., 216, 808-813 (1995) https://doi.org/10.1006/bbrc.1995.2693
- D.H. Ho, W. Covington, N. Brown, S.N. Lin, R. Pazdur, Y.Y. Huo, P.J. Creaven, Y.M. Rustum, N.J. Meropol, Y. Lassere, J. Kuritani and T. Hayakawa, Oral uracil and Ftorafur plus leucovorin: Pharmacokinetics and toxicity in patients with metastatic cancer, Cancer Chemother Pharmacol, 46, 351-356 (2000) https://doi.org/10.1007/s002800000156
- J. Gu, H. Yuasa, Y. Hayashi and J. Watanabe, First-pass metabolism of 5-fluorouracil in the perfused rat small intestine, Biol. Pharm. Bull., 21, 871-873 (1998) https://doi.org/10.1248/bpb.21.871
- L.A. Celio, G.J. DiGregorio, E. Ruch, J.N. Pace and A.J. Piraino, 5-Fluoroumcil concentrations in rat plasma, Parotid saliva, and bile and protein binding in rat plasma, J. Pharm. Sci., 72, 597-599 (1983) https://doi.org/10.1002/jps.2600720605
- H. Yuasa, K. Matsuda, J. Gu, E. Suzuki, I. Yokouchi and J. Watanabe, Dose-dependent gastrointestinal absorpdon of 5- fluorouracil in rats in vivo, Biol. Pharm. Bull., 19, 1494-1498 (1996) https://doi.org/10.1248/bpb.19.1494
- R.F. Murphy, F.M. Balis and D.G. Poplack, Stability of 5-fluorouracil in whole blood and plasma, Clin Chem., 33, 2299-2300 (1987)
- J.M. Collins, R.L. Dedrick, F.G. King, J.L. Speyer and C.E. Myers, Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intrapentoneal routes, Clin Pharmacol Ther, 28, 235-246 (1980) https://doi.org/10.1038/clpt.1980.156
- G. Milano and A.L. Chamorey, Clinical pharmacokinetics Of 5-fluorouracil with consideration of chronopharmacokinetics, Chronobiol Int., 19, 177-189 (2002) https://doi.org/10.1081/CBI-120002597
- K. IKeda, K. Yoshisue, E. Matsushima, S. Nagayama, K. Kobayashi, C.A. Tyson, K. Chiba and Y. Kawaguchi, Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro, CIin Cancer Res., 6, 4409-4415 (2000)
- H. Yamazaki, T. Komatsu, K. Takemoto, N. Shimada, M. Nakajima and T. Yokoi, Rat cytochrome P-450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes, Drug Metab. Dispos., 29, 794-797 (2001)
- D.H. Ho, R. Pazdur, W. Covington, N. Brown, Y.Y. Huo, Y. Lassere and J. Kuritani, Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil, Clin Cancer Res., 4, 2085-2088 (1998)
피인용 문헌
- Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling vol.22, pp.9, 2017, https://doi.org/10.3390/molecules22091488